We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

GMP PROTEIN (E. COLI) CONTRACT MANUFACTURING MARKET ANALYSIS

GMP Protein (E. coli) Contract Manufacturing Market, by Product Type (Cytokines, Growth Factors, Enzymes [DNA polymerase, Protease, Trypsin, Nuclease {Benzonase, Cas9 Nucleases, and Others}, IVT Enzymes, and Others] Hormones, Antigens, and Others), by Application (Gene Therapy and Cell Therapy), by Method (In-Vivo and Ex-Vivo), by End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • Published In : Dec 2022
  • Code : CMI5433
  • Pages :603
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Market News

Global GMP Protein (E. coli) Contract Manufacturing Market: Key Developments

In June 2021, Vectron Biosolutions AS, a company developing and marketing vector technologies for the biotechnology and life science industries, announced that it had raised US$ 2.7 million in a Series A financing round led by Dynamk Capital along with the acquisition of a bacterial secretion platform from T3S TECHNOLOGIES, INC., a biotechnology company. The acquisition of T3S Technologies’ secretion platform combined with Vectron’s core expression technology and additional financing will significantly help Vectron to reduce costs associated with the production of recombinant proteins or solutions to advance their challenging proteins to the market.

In November 2019, Abcam plc., a supplier of protein research tools to life scientists, announced a strategic partnership with BrickBio, Inc., a developer of a bioconjugation platform intended for research of site-specific modification of proteins. As a part of the partnership, Abcam plc. will have exclusive rights to the proprietary platform for introducing conjugation-ready sites into antibodies and other proteins in both mammalian and bacterial expression systems for the creation of novel conjugation-ready recombinant products for the research tools market. In addition, it will have the right to commercialize the platform across its recombinant antibody and protein portfolio for diagnostic purposes. BrickBio’s platform can site selectively modify proteins in a broad range of eukaryotic and bacterial cell lines. Using a proprietary engineered tRNA synthetase/tRNA pair, the platform can easily incorporate unnatural amino acids that can then be coupled to a second molecule for labeling or other research applications or to create protein-conjugate therapeutics including Antibody-Drug-Conjugates (ADCs).

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.